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Abstract
Background: Different subsets of tumor infiltrating T lymphocytes are believed to play essential role in the
immune response to cancer cells. The data of these cells in NSCLC are relatively rare and controversial therefore we
aimed to evaluate the infiltration patterns of Foxp3 + CD4+, CD4+ and CD8+ T cells in NSCLC and to analyze their
relations to survival.
Methods: Lung tissue specimens from 80 newly diagnosed and untreated patients who underwent surgery for
NSCLC (stages I-III), and 16 control group subjects, who underwent surgery due to recurrent spontaneous
pneumothorax, were analyzed. Foxp3 + CD4+, CD4+ and CD8+ T cells in tumor stroma and islets were evaluated
immunohistochemically. All statistical analyses were performed using the Statistical Package for the Social Sciences
(SPSS), version 20.0.
Results: Tumor infiltrating CD4+, CD8+ T cells were associated with neither overall survival nor disease-free survival.
The presence of high tumor stroma infiltrating Foxp3 + CD4+ T cells was independently associated with improved
NSCLC patients overall survival (P < 0.05).
Conclusions: Our study demonstrated that tumor infiltrating Foxp3 + CD4+ T cells are associated with improved
NSCLC patients' survival. In addition our findings highlight a tendency of high CD4+/CD8+ and CD8+/Foxp3 +
CD4+ T cells ratio in prolonged NSCLC patients' survival.
Keywords: Non-small cell lung cancer, Foxp3 + CD4+ T cells, CD4+ T cells, CD8+ T cells, Tumor islets and stroma,
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Introduction
Lung cancer is most frequent carcinoma and leading cause
of cancer-related mortality. Immune responses within the
tumor microenvironment are increasingly implicated as de-
termining factor in tumor progression and aggressiveness.
Understanding these responses has allowed investigators to
use immune markers to stratify the prognosis of NSCLC
patients [1]. Tumor-associated immune response is pivotal
factor in tumor progression. Tumor infiltrating T lympho-
cytes play an important role in modeling antitumor im-
mune response. As the survival of NSCLC remains very
poor despite the newest anticancer treatment, prognostic
markers are required to distinguish the patients with poor
and good prognosis in order to choose the better treatment
and follow-up strategy. Different subsets of tumor infiltrat-
ing T lymphocytes are believed to play essential role in the
immune response to cancer cells.
However, tumor progression, which often also is seen in
the presence of substantial lymphocytic infiltration, sug-
gests that T cells are not capable provide effective immune
responses to control tumor growth [2]. Evidence has accu-
mulated that tumor infiltrating T lymphocytes are func-
tionally defective, incompletely activated, and include
regulatory subtypes, which varied with the types of can-
cers [3–5]. Therefore, if distinctions were made with re-
spect to lymphocyte types, location, functional state, and
* Correspondence: jjackute@gmail.com
1Department of Pulmonology and Immunology, Medical Academy,
Lithuanian University of Health Sciences, Kaunas, Lithuania
Full list of author information is available at the end of the article
© 2015 Jackute et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Jackute et al. Journal of Inflammation  (2015) 12:63 
DOI 10.1186/s12950-015-0108-x
their interactions, a more profound impact on prognosis
was observed compared with only the overall degree of
lymphoid infiltration [6]. Recently Foxp3+CD4+ T cells
became an object of great interest in studies of different
cancer types as well as in NSCLC. It is thought that
Foxp3+CD4+ T cells have the ability to suppress or regu-
late cell-mediate immunity [7]. After migrating to tumor
site, Foxp3+CD4+ T cells can inhibit the activity of cyto-
toxic T cells through cell-to-cell contact. However differ-
ent mechanisms by which Foxp3+CD4+ T cells suppress
antitumor immune response exist, but still not fully
understood yet [8]. Although Foxp3+CD4+ T cells can po-
tentially promote cancer progression, they can also attenu-
ate inflammation. Because chronic inflammation is one of
the critical processes promoting carcinogenesis and tumor
growth, Foxp3+CD4+ T cells are able to down-regulate the
pro-tumorigenic inflammatory responses.
Some Foxp3+CD4+ T cells associated molecules are in-
volved in carcinogenesis process such as IL-10 and TGFβ
[9]. IL-10 is related with impaired antigen presentation for
proper activation of T cells and T cell proliferation; TGFβ
may suppress natural killer cell function. Hatanaka et al.
[10] found that NSCLC patients have elevated IL-10
serum levels compared to healthy controls which has been
associated with poorer prognosis. Nevertheless, data con-
cerning the role of IL-10 for tumor progression are par-
tially inconsistent. In contrast to these results, some
studies suggest that IL-10 is important for tumor rejection
[11, 12]. Despite these contradictions, the immune-
suppressive cytokine is an important factor during the in-
duction of airway tolerance. Therefore, it is necessary to
further define the role of IL-10 in NSCLC [9].
Tumor-infiltrating CD4+ and CD8+ T cells play im-
portant role in the immune response to cancer cells in
NSCLC. As CD8+ T cells exhibit marked cytotoxic cap-
acities that may induce tumor cell death [13], by releas-
ing perforins and granzymes in acquired immune
responses, thereby playing a critical role in antitumor
immunity [14]. Indeed, CD8+ T cells are most likely
functionally relevant in NSCLC, as the number of apop-
totic tumor cells was significantly higher in tumors with
a high number of CD3+ and CD8+ T cells [15] therefore
CD8+ T lymphocytes comprise a well-established group
of effector T cells with potent cytotoxic effects in cancer
[16]. However, the presence of CD8+ T cells in NSCLC
has been identified as positive, neutral or negative prog-
nostic marker [17–19]. Another important factor affect-
ing clinical outcomes in NSCLC might be tumor
infiltrating CD4+ T cells. These cells produce immuno-
regulatory cytokines such IFN-gamma and TNF that
may induce cytolytic CD8+ T cell responses in lung can-
cer [14, 20]. Another important factor effecting clinical
outcomes in NSCLC might be relatinship between CD4+
and CD8+ T cells due to synergistic compartment [20].
The data of these cells in NSCLC are relatively rare
and controversial therefore we aimed to evaluate the in-
filtration patterns of Foxp3+CD4+, CD4+ and CD8+ T
cells in tumor islets and stroma from patients with
NSCLC and to analyze their relations to survival.
Material and methods
Subjects
Lung tissue specimens from 80 newly diagnosed and un-
treated NSCLC patients who underwent surgical resection
for NSCLC (pathological stage I-III) and 16 control group
subjects who underwent surgery due to recurrent spontan-
eous pneumothorax at the Hospital of Lithuanian Univer-
sity of Health Sciences, Kaunas Clinics from September
2012 to April 2015 were studied. For eligible patients,
demographic data including smoking habit, data on COPD
and other comorbidities were collected. Subjects were ex-
cluded if they had a history of another malignancy, con-
nective tissue diseases or any unstable systemic disease
(including active infections, significant cardiovascular dis-
ease). Peripheral venous blood samples were obtained be-
fore lung surgery. None of NSCLC patients received
preoperative radiotherapy or chemotherapy. Two qualified
pathologists evaluated lung specimens. Histological classi-
fication of tumors was based on the World Health
Organization criteria [21]. Tumors were staged according
to the TNM Classification of Malignant Tumors, the sev-
enth edition [22]. The clinical stage, tumor type were re-
corded at the time of diagnosis. NSCLC patients were
divided into two groups according to their COPD status:
NSCLC patients with COPD and NSCLC patients without
COPD. COPD was defined according to the criteria of the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) [23]. None of included subjects had an exacerba-
tion of COPD or clinical signs of an acute upper respira-
tory tract infection or had received systemic glucocorticoid
therapy 1 month before the surgery. At the same, patients
were divided into following two groups based on a smoking
history: nonsmokers and smokers. Patients who reported
smoking more than 100 cigarettes during their lifetime
were defined as smokers. Smoking history was calculated in
pack-years as the product of tobacco use (in years) and the
average number of cigarettes smoked per day divided by 20
(years x cigarettes per day/20). Pulmonary function was
tested by using a pneumotachometric spirometer “Custo-
vitM” (Custo Med, Germany). The highest value of forced
expiratory volume in 1 s (FEV1), forced vital capacity
(FVC) and FEV1/FVC ratio from three reproducible
measurements were recorded. The results were compared
with the predicted value matched for age, body height and
sex according to the standard methodology [24].
The study protocol was approved by Kaunas Regional
Ethics Committee for Biomedical Research (No. BE-2-20).
The study was registered in the U.S. National Institutes of
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Health trial registry ClinicalTrials.gov with identifier
NCT02214303.
Written informed consent was obtained from all study
subjects.
Immunohistochemical analysis
Lung tissue samples were fixed in formalin and, after dehy-
dration, embedded in paraffin. Tissue sections 3- to 5-μm
thick were cut, subsequently de-waxed and rehydrated
through graded alcohols. Slides immunohistochemically an-
alyzed for the expression of Foxp3+CD4+, CD4+ and CD8+
T cells. A Roche Ventana Benchmark XT automated slide
stainer (Ventana Medical Systems, Roche, France) was used
for immunohistochemistry. Immunohistochemical staining
was performed according to the manufacturer’s instruc-
tions. Monoclonal rabbit anti-human antibodies were used
for identification CD4+ T cells (anti-CD4, SP35, Ventana)
and CD8+ T cells (anti-CD8, SP57, Ventana). Immunohisto-
chemical double staining was performed to identify Foxp3
+CD4+ T cells using monoclonal rabbit anti-human anti-
bodies against the following proteins: CD4 (anti-CD4,
SP35, Ventana), Foxp3 (anti-Foxp3, SP97, Spring). Quanti-
tative evaluation of CD4+ and CD8+ T cells was done in 10
most representative high-power fields (HPFs × 400 magnifi-
cation) per tissue section using an Olympus BX50 micro-
scope (Olympus Co, Japan). The number of cells with
positive staining was counted manually in two locations:
tumor stroma and tumor islets (Figs. 1 and 2). Slides were
coded, and microscopic analysis was carried out blindly to
the clinical data.
Peripheral blood collection and detection of cytokine in
serum
Peripherial blood samples from all tested patients were col-
lected into sterile vacutainers without additives (2 × 5 mL)
and stored at room temperature for the surface clot
formation (about 30 min). Then tubes were centrifuged at
1000 × g for 10 min at room temperature. From the upper
layer of the sample the serum was vacuumed into sterile
cold-resistant Eppendorf tubes and stored at −70 °C for fur-
ther ELISA analysis.
The serum cytokine levels were measured by enzyme-
linked immunosorbent assay (ELISA) according to the
manufacturer’s instructions. The minimum detectable con-
centration of IL-10 was 3.57 pg/mL (IBL International, USA).
Statistical analysis
All statistical analyses were performed using the Statis-
tical Package for the Social Sciences (SPSS), version
20.0. The number of Foxp3+CD4+, CD4+ and CD8+ T
cells is presented as median with ranges. The associa-
tions between tumor-infiltrating Foxp3+CD4+, CD4+ and
CD8+ T cells and clinicopathologic characteristics were
analyzed using the chi-square (χ2) test. Differences
among all study groups were evaluated by using the
Kruskal-Wallis test or the Mann–Whitney U test for in-
dependent samples and the Wilcoxon test for related
samples. Multivariate logistic regression analysis was
used to identify factors independently associated with
the biomarkers of interest. The Kaplan-Meier method
Fig. 1 Foxp3+CD4+ T cells in non-small cell lung cancer tissue. Arrows
indicate positive double stained cells. Original magnification: ×400
B
A
Fig. 2 CD4+ and CD8+ T cells in non-small cell lung cancer tissue.
Arrows indicate CD4+ (a) and CD8+ (b) positive stained cells. Original
magnification: ×400
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with the log-rank test was used to calculate survival
rates and differences in survival curves, and P values
were determined by the log-rank test. P values of <0.05
were considered to indicate statistical significance.
Results
Characteristics of studied subjects
Demographic, clinical, and histological characteristics of
studied subjects are shown in Table 1. The groups of
study patients were homogenous, except for age and
smoking pack-years. Our study included 38 patients with
adenocarcinoma, 36 patients with squamous cell carcin-
oma, 5 patients with large cell carcinoma, and 1 patient
with adenosquamous carcinoma (the latter two were
grouped in other histological group).
Foxp3+CD4+T cells infiltration in NSCLC and control group
patients
While analyzing the NSCLC and control group patients,
we compared only total numbers of Foxp3+CD4+ due to
different morphological structure of tissue. NSCLC pa-
tients had a greater number of lung tissue-infiltrating
Foxp3+CD4+ T cells compared with the control group
(P < 0.001) (Fig. 3).
Foxp3+CD4+ T cells infiltration in tumor islets and stroma
Tumor-infiltrating Foxp3+CD4+ T cells were observed in
the tumor stroma as well as tumor islets with predomin-
ant infiltration in the tumor stroma (Table 3). There was
no association between the numbers of Foxp3+CD4+ T
cells in tumor stroma or islets and NSCLC patients’ gen-
der, age, pathological T status, lymph node status, histo-
logical tumor type, tumor differentiation and smoking or
COPD status (Tables 2 and 3).
In addition, there were significant correlations between
the total number of CD4+ T cells and Foxp3+CD4+ T
cells in islets (r = 0.26; P < 0.05). We found correlations
between CD4+ T cells in islets and Foxp3+CD4+ T cells
in islets (r = 0.58; P < 0.05), Foxp3+CD4+ T cells in
stroma (r = 0.25; P < 0.05) and total Foxp3+/CD4 T cells
(r = 0.44; P < 0.001).
Foxp3+CD4+ T cells infiltration and survival in NSCLC
Better survival was found for NSCLC patents with higher
Foxp3+CD4+ T cells infiltration in tumor islets, stroma or
higher total Foxp3+CD4+ T cells infiltration (P < 0.05). Since
previous studies have analyzed ratios between Foxp3+CD4+
and CD8+ T cells in relation to survival, we also calculated
the associations of the CD8+/Foxp3+CD4+ ratio with sur-
vival. Patients with higher CD8+/Foxp3+CD4+ ratio were
associated with better overall survival (P < 0.05).
CD4+ and CD8+ T cells infiltration in NSCLC and control
group patients
NSCLC patients had a greater number of lung tissue-
infiltrating CD4+ and CD8+ T cells compared with the
control group (P < 0.001) (Fig. 3).
Table 1 Patients characteristics
Variable NSCLC Healthy subjects
n = 80 n = 16
Gender n (%):
Female 16 (20) 3 (18.8)
Male 64 (80) 13 (81.2)
Age, years, median (range) 66 (45–77) 34 (19–77)**
Smoking history n (%)*
Non- smokers 14 (17.5) 10 (62.5)
Smokers 66 (82.5) 6 (37.5)
Smoking pack-years, median (range) 30 (0–60) 2,5 (0–50)**
FEV1 % of pred. median (range) 83 (33–144) 93 (70–114)
FEV1/FVC ratio % of pred., median (range) 89 (49–123) 107 (86–114)
Histological NSCLC type:
Adenocarcinoma 38 (47.5) _
Squamous cell carcinoma 36 (45)
Large cell carcinoma 5 (6.2)
Adenosquamous carcinoma 1 (1.2)
NSCLC stage:
Stage IA 4 (5.0) _
Stage IB 19 (23.8)
Stage IIA 21 (26.2)
Stage IIB 5 (6.2)
Stage IIIA 28 (35.0)
Stage IIIB 3 (3.8)
T status:














FEV1 forced expiratory volume in one second, FVC forced vital capacity
*P < 0.05, chi-square (χ2) test
**P < 0.05, Mann–Whitney U test
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CD4+ and CD8+ T cells infiltration in tumor islets and stroma
Predominant infiltration of CD4+ T cells as well as CD8+
T cells was observed in tumor stroma compared to
tumor islets (P < 0.001). CD8+ T cells predominated over
CD4+ T cells in the tumor islets (P < 0.001), but no sig-
nificant difference between the numbers of these cells
was found in the tumor stroma. There was no
association between the numbers of CD4+ and CD8+ T
cells in tumor stroma or islets and NSCLC patients’ gen-
der, age, pathological T status.
Smoking patients with NSCLC had a significantly
greater number of tumor stroma-infiltrating CD4+ T
cells than nonsmokers with NSCLC (P < 0.05). Also
greater number of CD8+ T cells in cancer stroma and
Fig. 3 Distribution of total CD4+, CD8+ and Foxp3+CD4+ T cells in lung tissue of NSCLC and control group subjects
Table 2 Association between total CD4+, CD8+ and Foxp3+CD4+ T cells and clinocopathological characteristics
Median, (range) CD4+ T cells P Median, (range) CD8+ T cells P Median, (range) Foxp3+CD4+ T cells P
Gender:
Female 164 (29–456) NS 195 (68–406) NS 43 (7–88) NS
Male 209 (27–538) 244 (59–499) 48 (6–92)
Smoking status:
Smokers 116 (29–265) <0.05 138 (59–332) <0.05 11 (6–77) NS
Non-smokers 238 (27–538) 264 (67–499) 52 (6–92)
Histological NSCLC type:
Adenocarcinoma 215.5 (116–538) <0.05<0.05* 284.5 (134–405) NS 56.5 (11–88) NS
Squamous cell carcinoma 282.5 (119–522) 268.5 (109–499) 57 (16–92)
Other 176.5 (116–417) 288 (92–361) 45 (13–73)
pT status
pT1a-2b 232 (116–538) NS 251 (92–406) NS 57 (11–92) NS
pT3-4 238 (116–474) 268.5 (137–499) 53 (16–90)
Lymph node status:
Negative (N0) 234 (125–522) NS 239 (109–403) NS 57 (11–90) NS
Positive (N1-N3) 235 (116–538) 270 (92–499) 55 (13–92)
Diferenciation:
Poor 253 (116–538) NS 257.5 (109–499) NS 56 (11–92) NS
Other 212 (116–504) 253 (92–406) 58 (13–88)
COPD:
Present 222.5 (116–538) NS 273 (123–405) NS 56 (16–88) NS
Absent 282 (126–522) 241.5 (92–499) 56.5 (11–92)
*P < 0.05, Mann–Whitney test for difference between adenocarcinoma and squamous cell carcinoma
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total tumor infiltrating CD8+ T cells was found in smok-
ing NSCLC patients compared to non-smokers NSCLC
patients (P < 0.05) (Table 3).
More CD8+ T cells in tumor stroma were presented in
NSCLC with COPD comparing with NSCLC without
COPD patients, and contrary, more CD8+ T cells in tumor
islets were found in NSCLC patients without COPD com-
pared to NSCLC patients with COPD (P < 0.05) (Table 3).
While analyzing the total number of CD4+ T cells, they
were more frequently found in squamous cell carcinoma
than adenocarcinoma (P < 0.05) (Table 2). CD4+ T cells
were found more abundantly in the stroma of squamous
cell carcinoma compared with adenocarcinoma (P < 0.05)
(Table 3).
Also greater number of CD8+ T cells in cancer stroma
was found in NSCLC patients with lymph node metasta-
ses compared to NSCLC patients without lymph node
metastases (P < 0.05) (Table 3).
In addition, there were significant correlations between
the total number of CD4+ T cells and CD8+ T cells in
islets (r = 0.39; P < 0.001) as well as in stroma (r = 0.36;
P < 0.05) and total CD8+ T cells (r = 0.47; P < 0.001).
CD4+ T cells in stroma correlated with CD8+ T cells in
islets (r = 0.36; P < 0.05) in stroma (r = 0.36; P < 0.05) and
in total (r = 0.46; P < 0.001).
CD4+ and CD8+ T cells infiltration and survival in NSCLC
It was found that CD4+ and CD8+ T cells were not
associated with overall survival. Patients with higher
CD4+/CD8+ ratio were associated with better overall
survival (P < 0.05).
IL-10 levels in serum
We examined serum IL-10 in NSCLC patients and com-
pared with taht in control group patients. NSCLC patient
had remarkably higher levels of serum IL-10 concentra-
tion (Fig. 4).
Also we investigated correlations between tumor infiltrat-
ing T cells and serum IL-10. We found correlation between
total CD4+ T cells count and IL-10 (r = 0.67; P < 0.001).
Table 3 Association between CD4+, CD8+ and Foxp3+CD4+ T cells number within cancer islets and stroma and clinicopathological
charateristics
CD4+ T cells median, (range) CD8+ T cells median, (range) Foxp3+CD4+ T cells median, (range)
Islets Stroma Islets Stroma Islets Stroma
Gender:
Female 27 (11–74) 162 (99–421) 35.5 (16–138) 181.5 (76–319) 12.5 (0–27) 44.5 (11–69)
Male 18 (11–82) 222 (98–489) 39 (10–219) 218 (80–374) 12 (1–35) 41 (12–72)
Smoking status:
Smokers 18 (11–82) 239 (98–489)** 38 (10–219) 223 (80–374)** 11.5 (0–27) 42.5 (11–63)
Non-smokers 34 (11–74) 138.5 (99–221) 34.5 (16–111) 162 (76–290) 12 (1–35) 41 (12–72)
Histological NSCLC type:
Adenocarcinoma 17.5 (11–80) 187 (98–458)*,** 39 (10–151) 201.5 (111–374) 11.5 (0–27) 41 (11–69)
Squamous cell carcinoma 18.5 (11–82) 261 (105–489) 36.5 (15–219) 226 (80–362) 13 (3–35) 41 (13–72)
Other 42 (15–57) 127.5 (101–392) 39.5 (16–86) 241 (76–324) 11.5 (1–24) 30.5 (12–63)
pT status
pT1a-2b 19.5 (11–82) 209 (101–489) 38 (15–151) 206 (76–369) 12.5 (0–32) 44 (11–72)
pT3-4 19.5 (12–69) 213 (98–453) 38 (10–219) 225.5 (115–374) 11.5 (1–35) 40 (13–63)
Lymph node status:
Negative (N0) 22 (11–78) 215 (98–444) 39 (10–142) 189 (80–374)** 11 (0–35) 42 (11–63)
Positive (N1-N3) 17 (12–82) 205 (99–489) 37 (15–219) 229 (76–369) 13 (1–32) 41 (12–72)
Diferenciation:
Poor 19.5 (11–82) 223 (98–458) 35.5 (10–219) 207.5 (80–374) 13 (0–35) 40 (11–69)
Other 18 (11–69) 189 (101–489) 39 (15–111) 210 (76–324) 12 (1–25) 43 (12–72)
COPD:
Present 21.5 (11–80) 191.5 (98–458) 40 (16–219)** 196 (76–374)** 12 (0–35) 40.5 (11–63)
Absent 17 (11–82) 266 (109–489) 34.5 (10–75) 240.5 (101–369) 12 (3–25) 42.5 (13–72)
*P < 0.05, Kruskal-Wallis test
**P < 0.05, Mann–Whitney test
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CD4+ T cells in stroma correlated with IL-10 (r = 0.66; P <
0.001). CD8+ T cells in islets correlated with IL-10 (r = 0.28;
P < 0.05).
To investigate the association between overall survival
of NSCLC patients and immune cell infiltration, multi-
variate logistic regression analysis was performed. A high
level of Foxp3+CD4+ T cells infiltration in the tumor
stroma was found to be independently associated with
the better overall survival (Exp(B), 3.69; 95 % CI of
Exp(B), 1.05–12.96; P = 0.041).
Discussion
The goal of our study was to examine tumor infil-
trating Foxp3+CD4+, CD4+ and CD8+ T cells by im-
munohistochemistry in specimens of NSCLC patients and
evaluate the prognostic value of these cells especially of
Foxp3+CD4+ .
In agreement with earlier reports, the current study
confirmed the the importance of CD8+, CD4+ and
Foxp3+CD4+ T cells as prognostic factors. The novelty
of our study was that these cells were examined in both
normal and malignant tissues.
Differently from normal tissue, lung tumors have two
distinct but interdependent compartments: the paren-
chyma (neoplastic cells) and the stroma that the neoplas-
tic cells induce and in which they are dispersed, that is
why while analyzing control and NSCLC groups we used
total number (in tumor islets and stroma) of Foxp3+CD4+,
CD4+ and CD8+ T cells. As expected, the numbers of
Foxp3+CD4+, CD4+ and CD8+ T cells were greater in the
NSCLC tissue than the lung tissue from control group
subjects. To our knowledge, there are no studies that
compared T cell infiltration in the lung tissue between
lung cancer patients and control subjects.
Foxp3+CD4+ T cells are generally considered to be im-
munosuppressive and have been linked to poor outcome
in several types of solid tumor also in NSCLC. The
major original findings of our study were that they are
associated with better survival.
Contrary to the putative pro-tumorigenic effect, the
presence of Foxp3+CD4+ T cells has been associated
with a good prognosis in colorectal and head and neck
cancers [25–27]. FOXP3 expression has been recently
described in normal cells and in non-hematopoietic-
derived cancer cells, suggesting that FOXP3 biological
effects are not restricted to Foxp3+CD4+ T cells. FOXP3
expression has been observed in different cancer histo-
types (NSCLC, breast, urinary bladder, tongue, gastric,
esophageal, pancreas, colorectal, stomach, thyroid, glioma
and melanoma). Tumor infiltration by Foxp3+CD4+T cells,
near-to-invariably detected by the immunohistochemical
detection of Foxp3+ lymphocytes, has been associated
with poor prognosis in cohorts of patients affected by
multiple distinct neoplasms, includ-ing Hodgkin lymph-
oma, melanoma as well as breast, gastric and ovarian car-
cinoma [25, 28–31].
Some authors reported good prognostic value of
Foxp3+CD4+ T cells in head and neck cancer [32, 33],
colorectal carcinoma [26, 34] bladder cancer [35] and
lymphoma [36]. In some tumor types including hepato-
cellular carcinoma and breast cancer, high levels of
intratumoral Foxp3+CD4+ T cells have been associated
with bad prognosis [37]. The discrepancy could arise
from the differences in methodologies or biological
properties of cancers. The FoxP3 was originally known
as a nuclear marker of CD4+CD25+ regulatory cells, but
compelling data have showed that it can also be
expressed in the effector or other helper T cells [38, 39]
indicating that apart from Foxp3+CD4+ T cells, FoxP3+
cells incorporate several other subgroups. Ronald J
reviewed 58 studies including 16 different malignant tu-
mors and found that the prognostic value of FoxP3 var-
ies widely even in the same cancer type. Nevertheless, in
four of these studies in which double labeling of FoxP3
combined with CD4+, CD25+ or CD8+ was applied, the
double-positive T cells were generally associated with a
poor prognosis except colorectal cancer [37]. These find-
ings suggest that Foxp3+CD4+ T cells might play a dual
role in carcinogenesis.
Various factors may explain these seemingly contradict-
ory observations. Intratumoral Foxp3+CD4+ T cells have
been shown to display a consistent degree of functional het-
erogeneity, which may obviously influence prognosis. Also
distinct subsets of Foxp3+CD4+ Tcells appear to specifically
control limited subsets of T cells [40]. Some cancers, such a
lymphoma, head and neck cancer, gastric cancer and
colorectal carcinoma has an important proinflammatory
component. Therefore Foxp3+CD4+ T cells mediated im-
munosuppression may exert antitumor functions. Some
studies showed that the ratio between tumor infiltrating
Fig. 4 Serum IL-10 concentration in NSCLC and control
group patients
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CD8+T cells and Foxp3+CD4+ T cells gives prognostic/
predictive information than either parameter alone. In par-
ticular, a high CD8+/Foxp3+CD4+ T cells ratio has been as-
sociated with favorable disease outcome in ovarian and
hepatocellular carcinoma patients [30, 41] and with a poor
prognosis in subjects affected by head and neck cancer [42].
Our study results showed that a high CD8+/Foxp3+CD4+ T
cells ratio has been associated with favorable disease out-
come (P < 0.05), meanwhile CD4+ or CD8+ T cells counts
separately didn’t significantly afected disease outcome.
Foxp3+CD4+ T cells may benefit the host by modulat-
ing inflammation, which is linked to the angiogenesis of
cancer [14].
Foxp3+CD4+ T cells inhibit the activation of both CD4+
and CD8+ T cells, and within the tumor microenvironment
may serve to suppress anti-cancer cell immunity. In some
murine tumors (melanoma and fibrosarcoma), both CD4+
and CD8+ T cells were found to be required for tumor
rejection. Since CD4+ and CD8+ T cells has been described
as a positive prognostic factor in NSCLC [43–45], we per-
formed an analysis of CD4+ and CD8+ T cells in relation to
disease survival. Tumor infiltrating CD4+, CD8+ T cells
were associated with neither overall survival nor disease-
free survival. Contrasted with the possible tumor-
promoting role of these cells in the progression of estab-
lished tumors, the role of Foxp3+CD4+ T cells in initial
tumor transformation caused by chronic inflammation
remains elusive. Based on the potent immunoregulatory
function these cells have on immune responses and in-
flammation, it is reasonable to conceive that Foxp3+CD4+
T cells may in fact help prevent or delay inflammation-
mediated tumor development. However, the experi-
mental evidence supporting this notion awaits further
investigation [46].
There are indications that IL-10 is reduced in patients
with NSCLC and that this reduction could correlate with
poor prognosis [11, 12]. However, up to now a connec-
tion between higher levels of IL-10 and better survival
could not been shown [47]. We did not find any associa-
tions between IL-10 and NSCLC patients outcomes.
Conclusions
Our study demonstrated that tumor infiltrating Foxp3+
CD4+T cells are associated with improved NSCLC pa-
tients’ survival. In addition our findings highlight a ten-
dency of high CD4+/CD8+ and CD8+/Foxp3+CD4+ T cells
ratio in prolonged NSCLC patients’ survival.
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